Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

 Cannabics Pharmaceuticals Inc. announced that it has completed a scan of selected RCKMC’s cannabis strains. Results obtained have shown that two specific strains have demonstrated higher anti-tumor activity.

The strains were examined at the company’s High Throughput Screening (HTS) facility located in Israel, in which their anti-tumor properties were examined on a wide range of cancers.  Analysis of the scans revealed specific cultivars which have a more significant necrotic effect on Gastric Adenocarcinoma cells.

The results will be used to further breed the selected cultivars for specific cancers, focusing on Gastric cancers. The cultivars to be developed will be the source for active pharmaceutical ingredients (API’s) for future clinical studies.